CYP3A4 and cancer: In an activity assay of CYP3A enzymes in the liver by a 14C-erythromycin phenotypic breath test in cancer patients with a C-reactive-protein level >10 mg/L, a decline of CYP3A enzymes’ activity by 30% was recorded as compared with patients without the acute phase response [271].